Select Page

Press Release

Acme Resources Announces Change of Name to Rapid Dose Therapeutics Corp. and Changes of Directors and Officers

View PDF

Toronto, Burlington Ontario – Further to its press release of December 7, 2018, Rapid Dose Therapeutics Corp. (formerly ACME Resources Corp.) (“ACME” or the “Corporation”), is pleased to announce the change of its name from ACME Resources Corp. to Rapid Dose Therapeutics Corp. in connection with the completion of its business combination with Rapid Dose Therapeutics Inc. (“RDT”).

In addition, the Corporation welcomes its new board members, Messrs. Mark Upsdell, Jason Lewis and Kenneth Fox. Brian Howlett is continuing as a director. As part of the transition of management in connection with the business combination with RDT, the new officers of the Corporation appointed today include Messrs. Mark Upsdell as President and CEO, Jason Lewis as SVP Business Development and Lino Fera as the CFO and Corporate Secretary. The new board wants to take this opportunity to thank the two directors who resigned today, John Siriunas and Kees Van Winters, and the officers who resigned today, John Siriunas, Miles Nagamatsu and Jorge Estepa, for their valuable contribution in managing the process to a successful completion of the business combination.

Having received conditional listing approval for its common shares to be listed on the Canadian Securities Exchange (the “CSE”), the Corporation continues to work on satisfying all necessary conditions, including delivery to the CSE of all final documentation for the listing, which is expected to be completed in the near future. Upon listing, the common shares of the Corporation will trade under the symbol “DOSE”.

A Game-Changing Delivery System

About Rapid Dose Therapeutics

Rapid Dose Therapeutics, RDT, is a Canadian bio-technology company that provides innovative, proprietary drug delivery technologies designed to improve patient outcomes and quality of lives. Rapid Dose Therapeutics offers Quick, Convenient, Precise and Discreet™ choices to consumers and patients. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn-key Managed Strip Service Program which enables RDT’s QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT is driven to expand globally into emerging markets, create value for both consumers and shareholders and continually create innovative solutions aimed at future market needs.

For further information see the Corporation’s profile at or visit:

For inquiries please contact:

Jorge Estepa
Assistant Corporate Secretary
Tel: 416 818-4035
1121 Walkers Line, Unit 3
Burlington ON Canada
L7N 2G4

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward- looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of ACME and RDT as to future events or results and are believed to be reasonable based on information currently available to them. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Back to press releases page